Lung eosinophilia pathways and inflammatory mediators

Lung eosinophilia pathways and inflammatory mediators refer to the integrated biological processes that drive the accumulation and activation of eosinophils in pulmonary tissues. This system is primarily governed by Type 2 (Th2) cytokines, including Interleukin-5 (IL-5), which is essential for eosinophil maturation and survival, and Interleukin-4 (IL-4) and Interleukin-13 (IL-13), which promote recruitment and airway hyperresponsiveness (Source: StatPearls, Eosinophilia, 2023). Chemokines like eotaxins (CCL11, CCL24) facilitate the migration of these cells from the blood into the lungs, where they release cytotoxic proteins such as major basic protein and eosinophil peroxidase (Source: UniProt, CCL11). In conditions like eosinophilic asthma, these pathways are pathologically overactive, leading to chronic inflammation and structural changes in the airways (Source: PubMed, PMC7357158). Therapeutic strategies target specific nodes in these pathways, such as IL-5 or the IL-4 receptor alpha, to effectively reduce eosinophil-mediated tissue damage and improve clinical outcomes (Source: FDA, Nucala/Dupixent Labels).

Other names

Eosinophilic airway inflammationType 2 inflammationTh2-mediated lung inflammationEosinophil recruitment cascade

Modulation of eosinophil activity through the antagonism of key signaling molecules such as IL-5, IL-4, and IL-13, or their receptors, thereby reducing eosinophil production, recruitment, and activation in the lungs (Source: PubMed, PMID: 32654302).